Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554

Dear shareholder,

Dear Madam, Dear Sir,

Confo Therapeutics (AvH 6%), a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of CFTX-1554. CFTX-1554 is a non-opioid approach to address chronic pain while avoiding centrally mediated side effects, such as addiction and sedation. As part of a global licensing agreement, CFTX-1554 is being developed with Eli Lilly and Company (Lilly).

Please find attached the press release of Confo Therapeutics.

Best regards

Ackermans & van Haaren

Attachment